TOFACITINIB ER 11 MG TABLET
For 30 tablets
Pharmacies pay
$65.78 filed
30 × $2.19263 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-02 · as of 2026-10-14 · retrieved 2026-10-17
Medicare
We don’t know yet
No Medicare reference price. Part D: OpenBill did not match this NDC to a usable Medicare Part D spending row. Either Part D has none for it, or the rows that share its name could not safely be tied to it (for example, they mix units, routes or release forms, or the drug is sold over the counter, which Part D does not cover). Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.
The spread
We don’t know yet
There is no Medicare figure to compare with, so there is no spread.
Cost-plus estimate
$80.65 estimated
$65.78 + $9.87 (15%) + $5.00 fee per fill = $80.65
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-02 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
TOFACITINIB ER 11 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “tofacitinib” and “tofacitinib citrate”, as its NDCs’ listings variously write the nonproprietary name, under the trade name “Tofacitinib XR”.
FDA gives its dosage form as “tablet, film coated, extended release” and “tablet, extended release” and its route as oral.
FDA lists 8 labelers (the companies named on the label) for its NDCs, among them Padagis US LLC, Ajanta Pharma USA Inc. and Edenbridge Pharmaceuticals LLC.
FDA’s Established Pharmacologic Class for it is Janus Kinase Inhibitor.
The NADAC file of 2026-10-14 prices it under 8 NDCs (National Drug Codes).
NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $65.78 for 30 tablets (30 × $2.19263 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-02. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 4, carried forward from the previous file.
The NADAC of all 8 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-09-02. The file is new; the price is not.
What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices
The 8 labelers
| Labeler | NDCs | Pharmacies pay per unit |
|---|---|---|
| Ajanta Pharma USA Inc. | 1 | $2.19263 per EA filed |
| Apotex Corp. | 1 | $2.19263 per EA filed |
| Aurobindo Pharma Limited | 1 | $2.19263 per EA filed |
| Biocon Pharma Inc | 1 | $2.19263 per EA filed |
| Edenbridge Pharmaceuticals LLC. | 1 | $2.19263 per EA filed |
| Exelan pharmaceuticals,Inc | 1 | $2.19263 per EA filed |
| Padagis US LLC | 1 | $2.19263 per EA filed |
| Zydus Pharmaceuticals USA Inc. | 1 | $2.19263 per EA filed |
All 8 NDCs, with labeler and price
- 00574-1811-30 · Padagis US LLC · $2.19263 per EA · eff. 2026-09-02 filed carried forward
- 27241-0270-30 · Ajanta Pharma USA Inc. · $2.19263 per EA · eff. 2026-09-02 filed carried forward
- 42799-0970-30 · Edenbridge Pharmaceuticals LLC. · $2.19263 per EA · eff. 2026-09-02 filed carried forward
- 59651-0685-30 · Aurobindo Pharma Limited · $2.19263 per EA · eff. 2026-09-02 filed carried forward
- 60505-4858-03 · Apotex Corp. · $2.19263 per EA · eff. 2026-09-02 filed carried forward
- 70377-0057-11 · Biocon Pharma Inc · $2.19263 per EA · eff. 2026-09-02 filed carried forward
- 70710-1353-03 · Zydus Pharmaceuticals USA Inc. · $2.19263 per EA · eff. 2026-09-02 filed carried forward
- 76282-0816-30 · Exelan pharmaceuticals,Inc · $2.19263 per EA · eff. 2026-09-02 filed carried forward
Other strengths, forms and brands
4 other products in the NADAC file share an FDA nonproprietary name with TOFACITINIB ER 11 MG TABLET.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| TOFACITINIB 5 MG TABLET | $0.57264 per EA filed | We don’t know yet |
| TOFACITINIB ER 11 MG TABLET this page | $2.19263 per EA filed | We don’t know yet |
| XELJANZ 5 MG TABLET | $73.77164 per EA filed | $93.68269 per EA filed |
| XELJANZ 10 MG TABLET | $103.93842 per EA filed | $93.68269 per EA filed |
| XELJANZ XR 11 MG TABLET | $207.89619 per EA filed | $190.71279 per EA filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-02, 2026-09-23, 2026-09-30 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
Compared with its class
The middle of its 8 NDCs’ NADAC prices is $2.19263 per EA filed.
Of the 10 other products in FDA’s Janus Kinase Inhibitor class priced per EA, 9 have a higher middle NADAC price and 1 a lower one. The one in the middle is OLUMIANT 4 MG TABLET, at $184.66233 per EA filed (eff. 2026-01-01).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-02 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
We don’t know yet; the card above says why.
Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.